Archive · 3 Dec 2025
Natco Pharma Faces Revenue Volatility Challenges
Natco Pharma is a company that makes special drugs, especially for cancer.
They use a risky but rewarding strategy where they challenge patents to sell generic versions of drugs early.
This can bring in a lot of money, but only for a short time.
Recently, their revenue and profits have dropped a lot because one of their big drugs, Revlimid, is facing more competition.
The company is trying to develop new drugs and expand to other countries, but it will take time to see the results.
Investors are worried because the company's future growth depends on a few key drugs and legal outcomes.
Natco Pharma's shares have dropped 38% from their 52-week high due to concerns about their high-risk business model.
The company focuses on complex, niche drugs and challenges patents to launch generic versions early, which can lead to significant earnings volatility.
Revenue fell from ₹1,371 crore in Q2FY25 to ₹475 crore in Q3FY25, with margins collapsing from 59% to 8%.
Revlimid, a blockbuster drug, contributed significantly to revenue but is now facing competition, leading to expected revenue and profit declines.
Natco is expanding its pipeline and entering new markets, but these efforts will take time to yield results.
- Who
- Natco Pharma Ltd
- What
- Faces revenue volatility due to its high-risk, high-reward business model
- When
- Recent financial performance and future outlook
- Where
- Primarily in the US market, with expansion into South Africa
- Why
- Dependence on limited-time drug opportunities and legal challenges
- Current Share Price
- ₹1,505 (52-week high)
- Revenue Drop
- ₹1,371 crore (Q2FY25) to ₹475 crore (Q3FY25)
- Margin Collapse
- 59% to 8%
- Revlimid Revenue Contribution
- 84% of total revenue in Q2FY26
- Expected Revenue (H2FY26)
- ₹750–800 crore
- Expected PAT (H2FY26)
- ₹135–150 crore
- P/E Ratio (FY27)
- 25x